Identification of Novel Markers of Human Lung Disease

NCT02369575 | Withdrawn

• 1 other identifier: 2014H0367
• Study Type: observational
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to investigate new therapies for advanced lung disease.

Conditions

Lung Diseases, Interstitial

Outcome Measures

Primary Outcomes (1)

• The development of novel therapeutics for interstial lung disease

  Our research on these human lung cells will provide critical data which will aid in the diagnosis and treatment of a variety of different lung diseases, which have no cure.

  10 years

Interventions

novel biomarkers of lung disease OTHER

we will be identifying molecular, genetic, and cellular markers of lung disease

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

patients on lung transplant waiting list

You may qualify if:

• any one on lung transplant list

You may not qualify if:

• HIV positive

Sponsors & Collaborators

• Ohio State University: lead

Study Sites (1)

Davis Heart and Lung Research Institute

Columbus, Ohio, 43210, United States

Location

Biospecimen

Retention: SAMPLES WITH DNA

lung cells

MeSH Terms

Conditions

Lung Diseases, Interstitial

Condition Hierarchy (Ancestors)

Lung Diseases; Respiratory Tract Diseases

Study Officials

• Megan Ballinger

  Ohio State University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Research Asst Professor

Study Record Dates

• First Submitted: February 17, 2015
• First Posted: February 24, 2015
• Study Start: February 1, 2015
• Primary Completion: July 1, 2025
• Study Completion: July 1, 2025
• Last Updated: July 29, 2025

Record last verified: 2025-07

Locations

US (1)